@article{Franceschi_Ehret_Visseaux_Durlach_Barbe_Durot_Grange_2022, title={Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas}, volume={102}, url={https://medicaljournalssweden.se/actadv/article/view/1087}, DOI={10.2340/actadv.v102.1087}, abstractNote={<p class="p1">Aggressive primary cutaneous T-cell lymphomas include advanced-stage mycosis fungoides (stage ≥ IIB mycosis fungoides), Sézary syndrome, gamma/delta cutaneous lymphoma, nasal type lymphoma, aggressive epidermotropic CD8<sup>+</sup> T-cell lymphoma and some cutaneous lymphomas not otherwise specified. To evaluate their long-term prognosis, we conducted a retrospective cohort study of 85 patients diagnosed between 2005 and 2020 with advanced-stage mycosis fungoides (<em>n </em>= 48), Sézary syndrome (<em>n </em>= 28) or aggressive non-mycosis fungoides/Sézary syndrome subtypes (<em>n </em>= 9). The median survival times in these 3 groups were 118.7, 45.7 and 11.2 months, respectively, and the 5-year survival rates were 55.3%, 27.8% and 33.3%, respectively. Multivariate analyses in patients with mycosis fungoides/Sézary syndrome identified age ≥ 70 years, Eastern Cooperative Oncology Group Performance Status ≥  2, and the high-risk group according to the Cutaneous Lymphoma International Consortium prognostic model, as adverse prognostic factors. Seven patients in this mycosis fungoides/ Sézary syndrome group were in complete long-term remission after treatment with bexarotene, including 4 patients living without any treatment for 16–101 months.</p>}, journal={Acta Dermato-Venereologica}, author={Franceschi, Joséphine and Ehret, Marine and Visseaux, Laetitia and Durlach, Anne and Barbe, Coralie and Durot, Éric and Grange, Florent}, year={2022}, month={Mar.}, pages={adv00676} }